Literature DB >> 33825512

BestFLR Trial: Liver Regeneration at CT before Major Hepatectomies for Liver Cancer-A Randomized Controlled Trial Comparing Portal Vein Embolization with N-Butyl-Cyanoacrylate Plus Iodized Oil versus Polyvinyl Alcohol Particles Plus Coils.

José Hugo Mendes Luz1, Filipe Veloso Gomes1, Nuno Vasco Costa1, Inês Vasco1, Elia Coimbra1, Paula Mendes Luz1, Hugo Pinto Marques1, João Santos Coelho1, Raquel Maria Alexandre Mega1, Vasco Nuno Torres Vouga Ribeiro1, Jorge Tiago Rodrigues da Costa Lamelas1, Maria Mafalda de Sampaio Nunes E Sobral1, Sílvia Raquel Gomes da Silva1, Ana Sofia de Teixeira Carrelha1, Susana Cristina Cardoso Rodrigues1, António Augusto Ferreira Pinto de Figueiredo1, Margarida Varela Santos1, Tiago Bilhim1.   

Abstract

Background In patients with liver cancer, portal vein embolization (PVE) is recommended to promote liver growth before major hepatectomies. However, the optimal embolization strategy has not been established. Purpose To compare liver regeneration as seen at CT in participants with liver cancer, before major hepatectomies, with N-butyl-cyanoacrylate (NBCA) plus iodized oil versus standard polyvinyl alcohol (PVA) particles plus coils, for PVE. Materials and Methods In this single-center, prospective, randomized controlled trial (Best Future Liver Remnant, or BestFLR, trial; International Standard Randomized Controlled Trial Number 16062796), PVE with NBCA plus iodized oil was compared with standard PVE with PVA particles plus coils in participants with liver cancer. Participant recruitment started in November 2017 and ended in March 2020. Participants were randomly assigned to undergo PVE with PVA particles plus coils or PVE with NBCA plus iodized oil. The primary end point was liver growth assessed with CT 14 days and 28 days after PVE. Secondary outcomes included posthepatectomy liver failure, surgical complications, and length of intensive care treatment and hospital stay. The Mann-Whitney U test was used to compare continuous outcomes according to PVE material, whereas the Χ2 test or Fisher exact test was used for categoric variables. Results Sixty participants (mean age, 61 years ± 11 [standard deviation]; 32 men) were assigned to the PVA particles plus coils group (n = 30) or to the NBCA plus iodized oil group (n = 30). Interim analysis revealed faster and superior liver hypertrophy for the NBCA plus iodized oil group versus the PVA particles plus coils group 14 days and 28 days after PVE (absolute hypertrophy of 46% vs 30% [P < .001] and 57% vs 37% [P < .001], respectively). Liver growth for the proposed hepatectomy was achieved in 87% of participants (26 of 30) in the NBCA plus iodized oil group versus 53% of participants (16 of 30) in the PVA particles plus coils group (P = .008) 14 days after PVE. Liver failure occurred in 13% of participants (three of 24) in the NBCA plus iodized oil group and in 27% of participants (six of 22) in the PVA particles plus coils group (P = .27). Conclusion Portal vein embolization with N-butyl-cyanoacrylate plus iodized oil produced greater and faster liver growth as seen at CT in participants with liver cancer, compared with portal vein embolization with polyvinyl alcohol particles plus coils, allowing for earlier surgical intervention. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Arellano in this issue.

Entities:  

Year:  2021        PMID: 33825512     DOI: 10.1148/radiol.2021204055

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  6 in total

1.  Reply to: Portal and Hepatic Vein Embolization to Accelerate Future Liver Remnant Hypertrophy-The Road Towards Level One Evidence.

Authors:  Remon Korenblik; Christiaan van der Leij; Ronald M van Dam
Journal:  Cardiovasc Intervent Radiol       Date:  2022-09-20       Impact factor: 2.797

Review 2.  Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

Authors:  Roberto Cannella; Lambros Tselikas; Fréderic Douane; François Cauchy; Pierre-Emmanuel Rautou; Rafael Duran; Maxime Ronot
Journal:  JHEP Rep       Date:  2022-04-04

3.  Portal vein embolization, biembolization, and liver venous deprivation.

Authors:  José Hugo Mendes Luz; Tiago Bilhim
Journal:  Radiol Bras       Date:  2021 May-Jun

4.  Portal Vein Embolization Using N-Butyl Cyanoacrylate-Glue: What Impact Does a Central Vascular Plug Have?

Authors:  Ulrik Carling; Bård Røsok; Sigurd Berger; Åsmund Avdem Fretland; Eric Dorenberg
Journal:  Cardiovasc Intervent Radiol       Date:  2021-12-14       Impact factor: 2.740

Review 5.  Current trends in regenerative liver surgery: Novel clinical strategies and experimental approaches.

Authors:  Jan Heil; Marc Schiesser; Erik Schadde
Journal:  Front Surg       Date:  2022-09-07

6.  Predictive Factors for Hypertrophy of the Future Liver Remnant After Portal Vein Embolization: A Systematic Review.

Authors:  E A Soykan; B M Aarts; M Lopez-Yurda; K F D Kuhlmann; J I Erdmann; N Kok; K P van Lienden; E A Wilthagen; R G H Beets-Tan; O M van Delden; F M Gomez; E G Klompenhouwer
Journal:  Cardiovasc Intervent Radiol       Date:  2021-06-17       Impact factor: 2.740

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.